All In MedTech

Device Trial Radar · NCT03218397

Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia

Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia (RAPIDS-GN)

Last checked: Nov 19, 2026Latest source record: Nov 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

500

Actual

Start

Oct 9, 2017

Primary completion

Nov 3, 2018

Study completion Nov 30, 2018

Sponsor

Lead sponsor
Duke UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID); Vanderbilt University
First posted
Jul 14, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (care provider)
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RAPIDS-GN is a multi-center, prospective, randomized, controlled trial to evaluate the following strategies for patients with confirmed gram-negative bacillus bacteremia (GNB): 1. Standard culture and antimicrobial susceptibility testing (AST); or 2. Rapid identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX)

Conditions

  • Gram-negative Bacteremia

Interventions

  • Accelerate PhenoTest™ BC KitDevice

    Rapid identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX)

  • Standard Culture and ASTDevice

    Standard culture and antimicrobial susceptibility testing (AST)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hours to First Antibiotic ModificationTime frame: 72 hours after randomization

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Los Angeles

    Los Angeles, California

  • Mayo Clinic

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.